mRNA-1365

Phase 1RNA therapy

Moderna

mRNA-1365 is one of 4 biologic programs targeting Respiratory Syncytial Virus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Syncytial VirusActive, not recruiting

Respiratory Syncytial VirusPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

Placebp

Pfizer

Phase 3

1 2

Mrna-1345

Moderna

Phase 1

3 3

Nimenrix

GSK

Phase 1

2 4

mRNA-1365

Moderna

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Active, not recruiting

Respiratory Syncytial Virus

NCT05743881

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, not recruiting· Moderna logo

Moderna·Phase 1·NCT05743881·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-1365. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1365 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1365. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: Moderna

mRNA-1365

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

References

Drug Info

Quick Facts

Related News